Updates on Adjuvant Osimertinib for NSCLC Treatment from the ADUARA Trial
Key opinion leaders share their thoughts on data updates from the ADUARA trial on the use of osimertinib as an adjuvant therapy for NSCLC.
EP: 1.Recommendations for Molecular Testing in Non-Small Cell Lung Cancer (NSCLC)
EP: 2.Molecular Testing in Early NSCLC to Guide Treatment Decision Making
EP: 3.Is There a Role for Liquid Biopsies in Early NSCLC?
EP: 4.Updates in the Treatment of Stage I-IIIA NSCLC
EP: 5.The Role of Neoadjuvant Therapy in Patients with Resectable NSCLC
EP: 6.Selecting Appropriate Patients with NSCLC for Neoadjuvant Therapy
EP: 7.The Role of Adjuvant Therapy in Patients with NSCLC
Now Viewing
EP: 8.Updates on Adjuvant Osimertinib for NSCLC Treatment from the ADUARA Trial
EP: 9.Adjuvant Therapy in EGFR-Mutated NSCLC
EP: 10.NSCLC Molecular Testing Recommendations for Community Hospitals
EP: 11.Exciting NSCLC Data Updates from ESMO 2022
Related Videos
Related Content
